DRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alpha Tau Medical Ltd (DRTS) is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has strong bullish momentum, but it is already technically overextended and lacks recent news or financial confirmation to support an immediate long-term entry. For an inpatient buyer, the current setup is better viewed as a hold than a fresh buy.
Technically, DRTS is in a bullish trend: MACD histogram is positive and expanding, and the moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. However, RSI_6 is 87.378, which is deeply overbought and suggests the stock has run too far too fast. Price at 13.33 is near the R2 resistance level of 13.609, which increases the risk of near-term cooling. The pattern-based trend data also signals weakness ahead, with an estimated 80% chance of -3.76% next day, -4.55% next week, and -16.67% next month.
Recent analyst sentiment is constructive, with multiple firms raising price targets and maintaining bullish ratings. Barclays raised its target to $17 and keeps Overweight, citing commercialization optionality from the Tolmar deal and attractive sales terms. Barclays also recently initiated coverage with Overweight and a $15 target. Earlier in May, Ladenburg and H.C. Wainwright both lifted targets and kept Buy ratings after encouraging trial updates. The company also appears to have a catalyst path tied to upcoming clinical readouts in 2026.
There is no recent news in the last week to drive fresh upside. The stock is technically overbought, trading close to resistance, and the pattern-based trend estimate points to downside over the next day, week, and month. Hedge fund and insider activity is neutral, with no meaningful buying support. There is also no recent congress trading data and no notable politician/influencer transactions reported.
No usable financial snapshot was provided, so latest-quarter revenue and growth cannot be assessed directly. The only financial-related detail available is from Piper Sandler's note on Q1 results, which mentioned an operating loss of $13.3M and cash of $80M. Based on that, the company appears to still be in a pre-commercial or development-stage profile, where cash burn matters more than near-term earnings. The latest quarter season was Q1 2026, but detailed financial growth data was not available.
Analyst sentiment is positive overall. Barclays is currently Overweight with a $17 target after initiation at $15, and other firms such as Ladenburg and H.C. Wainwright also have Buy ratings with targets in the $14-$15 range. Piper Sandler is more cautious with a Neutral rating and an $8 target after Q1 results, noting operating loss and ongoing clinical progress. Overall Wall Street view is bullish but not unanimous: pros emphasize commercialization potential and trial upside, while the main con is that the company remains early-stage and not yet supported by clear financial performance.
